Lung cancer represents the leading cause of cancer‐related deaths worldwide.1 A subgroup of non‐small lung cancer (NSCLC) patients have been reported to have activating EGFR mutations,2 and responded well to first‐generation EGFR tyrosine kinase inhibitors (EGFR‐TKIs). The gene discussed is EGFR; the disease is lung carcinoma.